Information  X 
Enter a valid email address

Cello Health PLC (CLL)

  Print          Annual reports

Wednesday 08 May, 2019

Cello Health PLC

AGM Statement

RNS Number : 2801Y
Cello Health PLC
08 May 2019
 

FOR IMMEDIATE RELEASE                                                                                         8 May 2019

 

 

 

Cello Health plc

("Cello" or the "Group")

 

AGM Statement

 

 

Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, announces that at the Annual General Meeting to be held later today Chairman Chris Jones will make the following statement:

 

"The Group has had a very good start to the year. For the first quarter, the Group has experienced good like-for-like net revenue and headline profit before tax growth. We are also confident regarding performance in the second quarter, and expect to report robust headline profit before tax growth for the first half of the year.

 

"At a segment operating level, Cello Health has had an excellent first quarter. In particular, the performances in our consulting businesses and in the US overall are notable. We expect the second quarter to continue this trend.

 

"Cello Signal has also made a solid start to the year in line with expectations.

 

"The Group's balance sheet remains strong, with better than expected cash conversion so far in 2019, continuing the strong cash conversion performance delivered in 2018. The Group continues to assess suitable acquisitive growth opportunities in the US.

 

"The Board is therefore confident of achieving a successful full year result in 2019, in line with expectations."

 

 

Enquiries:

 

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive

 

Mark Bentley, Group Finance Director

 

 

Cenkos Securities plc

020 7397 8900

Mark Connelly/Harry Hargreaves

 

 

 

Buchanan

Mark Court

020 7466 5000

Jamie Hooper

 

Sophie Wills

 

 

 

 

About Cello Health plc

 

We are a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

 

We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.

 

Cello Health plc delivers its services from an office network in the UK, USA, Germany and Asia, with hub offices in New York, Philadelphia, London, Berlin, Edinburgh, Farnham and Cheltenham.

 

For further information, please visit: https://cellohealthplc.com/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGMEAKSXEELNEFF

a d v e r t i s e m e n t